One procedure. A closer look.
Garadacimab was not included in the ACT, even though the G-BA had previously found an indication of a major added benefit of garadacimab versus berotralstat. This snapshot looks at how this constellation arose.
The appropriate comparator therapy for donidalorsen was based on the situation in March 2025
For donidalorsen, the G-BA determined routine prophylaxis with a C1 esterase inhibitor, lanadelumab or berotralstat as the ACT. The underlying comparator set dates back to a G-BA consultation in March 2025. The timeline of the procedure:
- March 2025: G-BA consultation on the ACT for donidalorsen.
- 21 August 2025: Garadacimab receives an indication of a major added benefit versus berotralstat.
- 1 March 2026: The benefit assessment of donidalorsen starts.
- 20 August 2026: The G-BA adopts its decision on donidalorsen. The ACT remains a C1 esterase inhibitor, lanadelumab or berotralstat.
Garadacimab had therefore already been approved and assessed for added benefit when the donidalorsen procedure started.
Why garadacimab was not included in the appropriate comparator therapy for donidalorsen
In its final decision on donidalorsen, the G-BA explicitly considered garadacimab but did not include it in the ACT. The G-BA referred to the absence of guideline-based recommendations and stated that the role of garadacimab in clinical practice could therefore not yet be conclusively assessed.
Whether berotralstat was still an appropriate comparator was itself discussed during the oral hearing on donidalorsen. For NICE, the pharmaceutical company had conducted an indirect comparison of donidalorsen versus garadacimab. In the German procedure, the question was raised why no corresponding comparison had been submitted. Berotralstat nevertheless remained part of the ACT.
As context, the German guideline on hereditary angioedema expired several years ago, and an update registered in 2023 has not yet been published. Garadacimab is therefore not reflected in the currently available German guideline.
What the donidalorsen comparator decision means for AMNOG evidence planning
The donidalorsen decision is relevant for AMNOG evidence planning because an early G-BA consultation reflects the ACT at a particular point in time. New approvals, G-BA decisions and guideline updates can change the evidence and treatment landscape before the subsequent benefit assessment begins.
In the donidalorsen procedure, these developments did not lead to an adjustment of the ACT. They do raise a broader question: When has the evidence and treatment landscape changed sufficiently to warrant reassessment of an already determined ACT?